论文部分内容阅读
目的探讨吉西他滨联合顺铂治疗乳腺癌术后的临床疗效。方法选取2007年1月至2009年6月我院收治的82例乳腺癌术后化疗患者的资料,随机分为两组,其中42例应用GP(吉西他滨联合顺铂)方案为治疗组,另40例应用CMF(环磷酰胺、5-氟尿嘧啶、氨甲喋呤)方案为对照组。21 d为1周期,所有患者均接受至少3个周期治疗;观察肿瘤有无复发,比较两组的有效率及毒副反应。结果GP组完全缓解26例,部分缓解13例,总有效率92.9%;对照组完全缓解18例,部分缓解13例,总有效率77.5%,GP组疗效明显优于CMF组,两组比较差异具有统计学意义(P<0.05)。两组的主要毒副反应均为恶心呕吐、脱发、骨髓抑制等,发生率无统计学差异。结论 GP在乳腺癌术后辅助化疗近期疗效满意,毒副反应可耐受。
Objective To investigate the clinical efficacy of gemcitabine and cisplatin in the treatment of breast cancer. Methods The data of 82 patients with postoperative chemotherapy of breast cancer who were admitted to our hospital from January 2007 to June 2009 were randomly divided into two groups, of which 42 patients were treated with GP (gemcitabine plus cisplatin) and the other 40 Case application of CMF (cyclophosphamide, 5 - fluorouracil, methotrexate) program for the control group. 21 d for a cycle, all patients received at least 3 cycles of treatment; observed tumor recurrence, the two groups were compared efficiency and toxicity. Results In the GP group, 26 cases were completely relieved, 13 cases were partially relieved, and the total effective rate was 92.9%. In the control group, 18 cases were completely relieved and 13 cases partially relieved. The total effective rate was 77.5%. The curative effect of GP group was better than that of CMF group. Statistically significant (P <0.05). The main side effects of both groups were nausea and vomiting, hair loss, bone marrow suppression, the incidence was no significant difference. Conclusion GP in the recent postoperative adjuvant chemotherapy for breast cancer with satisfactory results, toxic side effects can be tolerated.